Based on the R1 RCM Inc stock forecast from 10 analysts, the average analyst target price for R1 RCM Inc is USD 16.35 over the next 12 months. R1 RCM Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of R1 RCM Inc is Neutral, which is based on 5 positive signals and 6 negative signals. At the last closing, R1 RCM Inc’s stock price was USD 42.00. R1 RCM Inc’s stock price has changed by +193.50% over the past week, +193.50% over the past month and +298.48% over the last year.
No recent analyst target price found for R1 RCM Inc
No recent average analyst rating found for R1 RCM Inc
Company Overview R1 RCM Inc
R1 RCM Inc. provides technology-driven solutions for the financial performance and patient experience of health systems, hospitals, and physician groups. It provides operating partnership/end-to-end solutions, which manages multiple aspects of the revenue cycle to realize financial leverage and revenue improvement for hospital and physician customers. The company also offers modular solutions, including functional partnership, an outsourcing solutions for improvements across targeted revenue cycle areas for hospital and physician group customers; revenue recovery, to fast-track payer and patient cash collections; revenue optimization, a solution to uncover missed or underreported revenue; clinical integrity, used to improve documentation and coding accuracy to maximize earned revenue for the services provided; and regulatory navigation, a compliance-first solutions for government reimbursement accuracy, pharmacy savings, and compliance. R1 RCM Inc. was formerly known as Accretive Health, Inc. and changed its name to R1 RCM Inc. in January 2017. The company was incorporated in 2003 and is headquartered in Murray, Utah. As of November 19, 2024, R1 RCM Inc. was taken private. Read Less
R1 RCM Inc. provides technology-driven solutions for the financial performance and patient experience of health systems, hospitals, and physician groups. It provides operating partnership/end-to-end solutions, which manages multiple aspects of the revenue cycle to realize financi...Read More
Frequently Asked Questions About R1 RCM Inc (RCM) Stock
Based on ratings from 10 analysts R1 RCM Inc's stock is Buy . Stock Target Advisor's fundamental analysis is Neutral. The stock has 6 buy, sell and 6 hold ratings.
Unfortunately we do not have enough data on RCM's stock to indicate if its a good dividend stock.
Based on targets from 10 analysts, the average taret price for RCM is USD 16.35 over the next 12 months. The maximum analyst target price is USD 20 while the minimum anlayst target price is USD 14.
RCM stock's Price/Earning ratio is 1,199.00.
Our analysis grades RCM stock's Price / Earning ratio at F. This means that RCM stock's Price/Earning ratio is above 93% of the stocks in the Health Information Services sector in the NSD exchange.
Based on this RCM may be a overvalued for its sector.
The last closing price of RCM's stock was USD 42.00.
The most recent market capitalization for RCM is USD 6.04B.
Based on targets from 10 analysts, the average taret price for RCM is projected at USD 16.35 over the next 12 months.
This means that RCM's stock price may go down by -61.07% over the next 12 months.
We can't find any ETFs which contains R1 RCM Inc's stock.
As per our most recent records R1 RCM Inc has 29,400 Employees.
R1 RCM Inc's registered address is 434 W. Ascension Way, Murray, UT, United States, 84123.
You can get more information about it from R1 RCM Inc's website at https://www.r1rcm.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About R1 RCM Inc (RCM) Stock
Based on ratings from 10 analysts R1 RCM Inc's stock is Buy . Stock Target Advisor's fundamental analysis is Neutral. The stock has 6 buy, sell and 6 hold ratings.
Unfortunately we do not have enough data on RCM's stock to indicate if its a good dividend stock.
Based on targets from 10 analysts, the average taret price for RCM is USD 16.35 over the next 12 months. The maximum analyst target price is USD 20 while the minimum anlayst target price is USD 14.
RCM stock's Price/Earning ratio is 1,199.00.
Our analysis grades RCM stock's Price / Earning ratio at F. This means that RCM stock's Price/Earning ratio is above 93% of the stocks in the Health Information Services sector in the NSD exchange.
Based on this RCM may be a overvalued for its sector.
The last closing price of RCM's stock was USD 42.00.
The most recent market capitalization for RCM is USD 6.04B.
Based on targets from 10 analysts, the average taret price for RCM is projected at USD 16.35 over the next 12 months.
This means that RCM's stock price may go down by -61.07% over the next 12 months.
We can't find any ETFs which contains R1 RCM Inc's stock.
As per our most recent records R1 RCM Inc has 29,400 Employees.
R1 RCM Inc's registered address is 434 W. Ascension Way, Murray, UT, United States, 84123.
You can get more information about it from R1 RCM Inc's website at https://www.r1rcm.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for RCM !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
